Tapan K. Bera, Ph.D

Tapan K. Bera, Ph.D

  • Center for Cancer Research
  • National Cancer Institute
Laboratory of Molecular Biology


Dr. Bera's research objectives include understanding the molecular basis of cancer by identifying the genes involved in this process and translating this information for possible targeted therapy of cancer. His recent studies focus on the development of recombinant Fab-immunotoxin targeting lymphoma and multiple myeloma. Dr. Bera has generated several genetically modified mouse models to evaluate the function of cancer-associated genes as well as for preclinical evaluation of recombinant immunotoxin-targeting mesothelin.

Areas of Expertise

Antibody Engineering
Recombinant Immunotoxin
Multiple Myeloma


Selected Key Publications

Mesothelin is not required for normal mouse development or reproduction

Bera TK, Pastan I.
Mol Cell Biol. 20: 2902-6, 2000. [ Journal Article ]

A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2

Bera TK, Onda M, Brinkmann U, Pastan I.
J MolBiol. 281: 475-83, 1998. [ Journal Article ]

NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate

Bera TK, Das S, Maeda H, Beers R, Wolfgang CD, Kumar V, Hahn Y, Lee B, Pastan I.
Proc Natl Acad Sci U S A. 101: 3059-64, 2004. [ Journal Article ]

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

Bera TK, Onda M, Kreitman RJ, Pastan I.
Leuk Res. 38: 1224-9, 2014. [ Journal Article ]